Fresenius Medical Care AG(FMS)
搜索文档
Is Fresenius Medical Care AG & Co. (FMS) Stock Undervalued Right Now?
ZACKS· 2024-11-11 23:45
核心观点 - 投资者有自己的策略 会关注价值 增长和动量趋势来发现好公司 价值投资是受喜爱的策略 可通过相关指标发现被低估股票 Zacks开发的Style Scores系统能突出有特定特征的股票 如价值投资者会关注价值类别评分高的股票 结合高Zacks排名价值类别中A级是很强的价值股 以Fresenius Medical Care AG & Co.为例 其Zacks排名为2(买入)价值等级为A 其预期市盈率与行业平均相比显示可能被低估 加上盈利前景 是一只令人印象深刻的价值股 [1][2][3][4][5] 关于投资策略 - Zacks Rank注重盈利预估和预估修正来寻找强势股票 投资者有自己的策略 会关注价值 增长和动量趋势 [1] - 价值投资是受喜爱的策略 旨在识别被市场低估的公司 价值投资者依靠传统分析形式对关键估值指标寻找被低估股票以获取利润 [2] - Zacks开发的Style Scores系统可突出有特定特征股票 价值投资者会关注价值类别评分高的股票 结合高Zacks排名价值类别中A级是很强的价值股 [3] 关于Fresenius Medical Care AG & Co. - 公司Zacks排名为2(买入)价值等级为A 预期市盈率为11.85 行业平均预期市盈率为32.83 过去一年其预期市盈率最高16.85最低10.51中位数为11.95 [4] - 这些数据表明公司目前可能被低估 加上盈利前景 是令人印象深刻的价值股 [5]
Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises
ZACKS· 2024-11-07 01:11
Fresenius Medical Care AG & Co. (FMS) reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which surpassed the Zacks Consensus Estimate by 7.1%. The bottom line improved 45.2% year over year.During the reported quarter, the company’s closed divestments included clinic operations in Curacao, Guatemala and Peru.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Revenue DetailRevenues of $5.23 billion (EUR 4,760 million) missed the Zacks Consensus Estimate by 2.4%. T ...
Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy?
ZACKS· 2024-11-06 23:55
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...
Fresenius Medical Care AG(FMS) - 2024 Q3 - Earnings Call Transcript
2024-11-06 03:34
财务数据和关键指标变化 - 第三季度实现有机收入增长2%,但由于剥离资产,收入在基准上下降0.7% [22][18] - 操作收入在基准上增长10%,操作收入率达到9.8%,接近2025年目标的10%至14% [23][20] - 净财务债务进一步减少,净杠杆比率改善至2.8倍,低于自设目标区间 [32][33] 各条业务线数据和关键指标变化 - 在护理交付业务中,美国市场的有机收入增长1%,国际业务实现4%的有机增长 [27][30] - 护理交付的操作收入增长5%,操作收入率提升至11.2% [28] - 护理赋能业务实现4%的有机收入增长,操作收入显著增长,几乎是去年同期的四倍 [31] 各个市场数据和关键指标变化 - 美国市场的同市场治疗增长转为正值,达到0.2% [10][18] - 国际市场的同市场治疗增长加速至3%,显示出全球行业趋势依然稳固 [11][12] 公司战略和发展方向和行业竞争 - 公司专注于运营表现的改善和转型,目标是到2025年实现650百万欧元的可持续节省 [19][35] - 公司计划在2025年推出HDF启用的5008X机器,预计在2026年全面商业化 [16] 管理层对经营环境和未来前景的评论 - 管理层对未来前景持乐观态度,尽管面临一些挑战,如价值基础护理业务的波动和通货膨胀压力 [14][20] - 管理层确认2024年收入增长展望,并将操作收入增长预期提高至16%至18% [20][34] 其他重要信息 - 公司在应对自然灾害方面表现出色,成功协调患者的透析治疗,尽量减少错过的治疗 [8][11] - 公司在美国的透析中心在CMS五颗星质量评级系统中表现优异,65%的中心获得3星或更高评级 [12] 问答环节所有提问和回答 问题: 中期利润率指导 - 管理层表示,尽管目前的利润率范围较宽,但仍然看到进入10%至14%上半部分的路径 [39][41] 问题: 护理赋能业务的利润率提升 - 管理层确认护理赋能业务的利润率提升将是后期集中发力的结果,预计将持续改善 [40][42] 问题: 飓风对第四季度的影响 - 管理层表示,第四季度的飓风影响预计与第三季度相似或略低 [44][45] 问题: 超额死亡率的影响 - 管理层指出,超额死亡率仍然高于COVID前水平,预计在未来几个月内会影响增长 [47][49] 问题: 新诊所的开设和人员配备 - 管理层表示,尽管存在人员配备挑战,但新诊所的人员配备情况有所改善 [52][53] 问题: 未来的资本配置 - 管理层强调,未来的资本配置将继续专注于减少债务,确保公司财务健康 [83][84] 问题: 同市场治疗增长的预期 - 管理层预计,随着死亡率的正常化,未来的同市场治疗增长将恢复到COVID前的水平 [56][94]
Fresenius Medical Care AG(FMS) - 2024 Q3 - Earnings Call Presentation
2024-11-06 01:49
业绩总结 - 2024年第三季度有机收入增长为1.9%,主要得益于护理赋能和护理交付[4] - 第三季度运营收入为4.19亿欧元,较2023年同期的3.32亿欧元增长[13] - 第三季度总收入为37.7亿欧元,较2023年同期的39.74亿欧元下降[13] - 2024年第三季度营业收入为4.63亿欧元,同比增长43%,营业收入率为9.7%[23] - 2024年第三季度税前收入为3.81亿欧元,同比增长62%[23] - 2024年第三季度净收入为2.13亿欧元,同比增长153%[23] - 2024年前9个月收入为142.51亿欧元,同比下降1%(按固定汇率下降1%)[25] - 2024年前9个月营业收入为11.33亿欧元,同比增长20%,营业收入率为8.0%[25] - 2024年前9个月税前收入为8.77亿欧元,同比增长27%[25] - 2024年前9个月净收入为4.71亿欧元,同比增长51%[25] - 2024年第三季度的净收入为879百万欧元,较2023财年的732百万欧元增长20.1%[33] 用户数据 - 美国的患者数量为205,942人,治疗次数为23,299,461次,较2023年持平[40] - 国际患者数量为102,274人,治疗次数为12,651,243次,较2023年下降25%[40] 财务状况 - 净财务杠杆比率进一步改善至2.8倍[4] - 第三季度运营现金流为9.85亿欧元,较2023年同期的7.6亿欧元增长[17] - 2024年第三季度的总债务和租赁负债为112.18亿欧元,较2023财年末的121.87亿欧元下降[31] - 2024年第三季度的净债务和租赁负债为98.31亿欧元,较2023财年末的107.60亿欧元下降[31] - 调整后的EBITDA为3,451百万欧元,较2023财年的3,391百万欧元增长1.8%[33] - 净负债与EBITDA比率为2.8,较2023财年的3.2有所改善[33] 未来展望 - 2024年全年运营收入增长预期调整为16-18%,接近之前范围的上限[4] - 2024年全年收入预期为低至中单位数百分比增长,基于2023年19亿欧元的基础[20] 负面信息 - 由于中国的基于量的采购引入,价格受到负面影响[3] 其他信息 - 第三季度FME25节省贡献为6400万欧元,超出全年目标[4] - 2024年第三季度的质量指数为81%,与2024年第二季度持平[38] - 2024年第三季度的贫血管理指标为72%,与2024年第二季度持平[38] - 2024年第三季度的血液透析有效性为94%,与2024年第二季度持平[38]
Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024
Prnewswire· 2024-11-05 20:00
Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income1 and operating income margin1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNe ...
Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock?
ZACKS· 2024-10-22 22:46
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional val ...
Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024
Prnewswire· 2024-10-21 23:04
A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments.Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.Nearly 75 abstracts presented across a broad range of cutting-edge research, covering topics from the global ...
Fresenius Medical Care: Let's Look At The Upside
Seeking Alpha· 2024-10-05 04:04
Analyst's Disclosure: I/we have a beneficial long position in the shares of FMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice ...
Here's Why Fresenius (FMS) is a Strong Momentum Stock
ZACKS· 2024-10-04 22:50
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...